CL2012000216A1 - Coloide compuesto de au/pt aleados, formado por mezcla de sal de oro y sal de platino con agente reductor de grupo de aminoacido, oligopeptido y aminoazucar en presencia de alcali; agente de rotulacion para inmunidad; anticuerpo o antigeno; y metodo para producir dicho coloide. - Google Patents

Coloide compuesto de au/pt aleados, formado por mezcla de sal de oro y sal de platino con agente reductor de grupo de aminoacido, oligopeptido y aminoazucar en presencia de alcali; agente de rotulacion para inmunidad; anticuerpo o antigeno; y metodo para producir dicho coloide.

Info

Publication number
CL2012000216A1
CL2012000216A1 CL2012000216A CL2012000216A CL2012000216A1 CL 2012000216 A1 CL2012000216 A1 CL 2012000216A1 CL 2012000216 A CL2012000216 A CL 2012000216A CL 2012000216 A CL2012000216 A CL 2012000216A CL 2012000216 A1 CL2012000216 A1 CL 2012000216A1
Authority
CL
Chile
Prior art keywords
colloid
salt
oligopeptide
antigen
antibody
Prior art date
Application number
CL2012000216A
Other languages
English (en)
Inventor
Masatoshi Watabe
Tetsuya Oda
Suguru Akamatsu
Original Assignee
Univ Kogakuin
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kogakuin, Otsuka Pharma Co Ltd filed Critical Univ Kogakuin
Publication of CL2012000216A1 publication Critical patent/CL2012000216A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0043—Preparation of sols containing elemental metal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Colloid Chemistry (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Coloide de Au/Pt formado por mezcla de sal de oro y sal de platino con agente reductor de grupo de aminoácido y derivado de éste, oligopéptido y derivado de éste, y aminoazúcar en presencia de alicali, se reduce sal de oro y sal de platino; agente de rotulación para análisis de inmunidad; anticuerpo o antígeno; método para producir coloide.
CL2012000216A 2009-07-29 2012-01-26 Coloide compuesto de au/pt aleados, formado por mezcla de sal de oro y sal de platino con agente reductor de grupo de aminoacido, oligopeptido y aminoazucar en presencia de alcali; agente de rotulacion para inmunidad; anticuerpo o antigeno; y metodo para producir dicho coloide. CL2012000216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009176812 2009-07-29

Publications (1)

Publication Number Publication Date
CL2012000216A1 true CL2012000216A1 (es) 2012-07-27

Family

ID=43529048

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000216A CL2012000216A1 (es) 2009-07-29 2012-01-26 Coloide compuesto de au/pt aleados, formado por mezcla de sal de oro y sal de platino con agente reductor de grupo de aminoacido, oligopeptido y aminoazucar en presencia de alcali; agente de rotulacion para inmunidad; anticuerpo o antigeno; y metodo para producir dicho coloide.

Country Status (13)

Country Link
US (1) US20120122245A1 (es)
EP (1) EP2461161A4 (es)
JP (1) JPWO2011013378A1 (es)
KR (1) KR20120051642A (es)
CN (1) CN102472748A (es)
AU (1) AU2010277031A1 (es)
CA (1) CA2766271A1 (es)
CL (1) CL2012000216A1 (es)
MX (1) MX2012001189A (es)
PE (1) PE20121391A1 (es)
RU (1) RU2012102938A (es)
WO (1) WO2011013378A1 (es)
ZA (1) ZA201200700B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113325179B (zh) * 2021-04-14 2024-02-27 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) 一种基于Au@Pt酶的免疫层析试纸条及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1303983C (en) * 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
JP4679716B2 (ja) * 2000-12-08 2011-04-27 日揮触媒化成株式会社 金属コロイド溶液の製造方法
JP3886000B2 (ja) 2002-03-08 2007-02-28 株式会社ビーエル 金属コロイド粒子
JP4145166B2 (ja) * 2003-02-28 2008-09-03 田中貴金属工業株式会社 一元系又は多元系金属コロイド及び一元系又は多元系金属コロイドの製造方法
CA2537199C (en) * 2003-08-28 2011-11-29 Tama-Tlo, Ltd. Precious metal colloid, precious metal microparticle, composition, and process for producing the precious metal microparticle
JP4180531B2 (ja) * 2004-02-19 2008-11-12 日本板硝子株式会社 金属コロイド粒子及びその製造方法
KR101378048B1 (ko) * 2007-07-06 2014-03-27 엠. 테크닉 가부시키가이샤 금속 미립자의 제조 방법 및 그 금속 미립자를 함유하는 금속 콜로이드 용액
JP2009085700A (ja) * 2007-09-28 2009-04-23 Fujifilm Corp イムノクロマトグラフキット
JP2009120901A (ja) * 2007-11-14 2009-06-04 Ne Chemcat Corp 金−白金コアシェルナノ粒子のコロイド、及びその製造法

Also Published As

Publication number Publication date
KR20120051642A (ko) 2012-05-22
RU2012102938A (ru) 2013-09-10
JPWO2011013378A1 (ja) 2013-01-07
EP2461161A1 (en) 2012-06-06
CA2766271A1 (en) 2011-02-03
MX2012001189A (es) 2012-03-07
EP2461161A4 (en) 2013-10-23
WO2011013378A1 (ja) 2011-02-03
CN102472748A (zh) 2012-05-23
ZA201200700B (en) 2013-05-29
PE20121391A1 (es) 2012-10-11
AU2010277031A1 (en) 2012-01-12
US20120122245A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido
BRPI0911431B8 (pt) composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
AR083114A1 (es) Produccion de anticuerpos de fucosa baja en celulas de rata h4-ii-e
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
SG178886A1 (en) Humanized anti-cdcp1 antibodies
BR112012013782A2 (pt) "antagonistas de pcsk9"
NZ588029A (en) Immuno-based botulinum toxin serotype a activity assays
NZ703581A (en) Anti-cd70 antibody drug conjugates
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MX357231B (es) Polipeptidos de anticuerpos que antagonizan el ligando cd40 (cd40l).
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
NZ705109A (en) Antibody formulations and uses thereof
BR112016002743A2 (pt) novo anticorpo de receptor de tslp anti-humana
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
BR112018001511A2 (pt) ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano
BR112012002429A2 (pt) polipeptídeos de porphyromonas gingivalis
EA201300138A1 (ru) Фармацевтическая композиция и метод ингибирования продукции или усиления элиминации белка p24
AR066863A1 (es) Metodo para detectar la presenc ia del componente de caliqueamicina de un conjugado del portador caliqueamicina en una muestra de fluido y kit para determinar la concentracion de la caliqueamicina presente en una muestra
ES2440393R1 (es) Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo